Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2015

01.08.2015 | Clinical Study

Low grade astrocytoma in children under the age of three years: a report from the Canadian pediatric brain tumour consortium

verfasst von: Donna L. Johnston, Daniel Keene, Ute Bartels, Anne-Sophie Carret, Bruce Crooks, David D. Eisenstat, Chris Fryer, Lucie Lafay-Cousin, Valerie Larouche, Albert Moghrabi, Beverly Wilson, Shayna Zelcer, Mariana Silva, Eric Bouffet

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

In children under the age of 3 years, the most common solid tumors are brain tumors. Low grade astrocytomas represent 30–40 % of brain tumours in this age group. This study reviewed the incidence, characteristics, therapy, and outcome of children less than 36 months of age diagnosed with a low grade astrocytoma from 1990 to 2005 in Canada. A data bank was established using data collected from Canadian pediatric oncology centers on children less than age 3 diagnosed with brain tumors between 1990 and 2005. Cases of low grade astrocytoma were extracted from this data bank and their characteristics summarized. From the 579 cases in the data bank, 153 cases of low grade astrocytoma (26 %) were identified. The mean duration of symptoms prior to presentation was 13 weeks, and 53 % of patients underwent a greater than 90 % resection of their tumor, while 30 % underwent 10–90 % resection. Seventy-one percent of patients received no further therapy after surgery and of the 45 who received therapy following surgery, 43 received chemotherapy, and 5 received radiation therapy. Sixty-eight patients had recurrence or progression of their tumor. Eighty-seven percent of patients were alive at the time of the survey with a 2 year survival rate of 95.3 ± 1.8 %, 5 year survival rate of 93.1 ± 2.1 % and 10 year survival rate of 89.1 ± 2.8 %. The 5 year survival rate for Canadian children less than 36 months of age with a low grade astrocytoma was 93.0 ± 2.8 % which is similar to that for older children with this tumor.
Literatur
1.
Zurück zum Zitat Ostrom QT, Gittleman H, Liau P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kurchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-Oncology 16:iv1–iv63PubMedCrossRef Ostrom QT, Gittleman H, Liau P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kurchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-Oncology 16:iv1–iv63PubMedCrossRef
2.
Zurück zum Zitat Hayostek CJ, Shaw EG, Scheithauer B, O’Fallon JR, Weiland TL, Schomberg PJ, Kelly PJ, Hu TC (1993) Astrocytomas of the cerebellum. A comparative clinicopathologic study of pilocytic and diffuse astrocytomas. Cancer 72:856–869PubMedCrossRef Hayostek CJ, Shaw EG, Scheithauer B, O’Fallon JR, Weiland TL, Schomberg PJ, Kelly PJ, Hu TC (1993) Astrocytomas of the cerebellum. A comparative clinicopathologic study of pilocytic and diffuse astrocytomas. Cancer 72:856–869PubMedCrossRef
3.
Zurück zum Zitat Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, Weingart JD, Repka MX, Cohen KJ, Burger PC (2008) Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 51:245–250PubMedCrossRef Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, Weingart JD, Repka MX, Cohen KJ, Burger PC (2008) Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 51:245–250PubMedCrossRef
4.
Zurück zum Zitat Villarejo F, Belinchon de Diego JM, Gomez de la Riva A (2008) Prognosis of cerebellar astrocytomas in children. Childs Nerv Syst 24:203–210PubMedCrossRef Villarejo F, Belinchon de Diego JM, Gomez de la Riva A (2008) Prognosis of cerebellar astrocytomas in children. Childs Nerv Syst 24:203–210PubMedCrossRef
5.
Zurück zum Zitat Rivera-Luna R, Zapata-Tarres M, Medina-Sanson A, Lopez-Aguilar E, Niembro-Zuniga A, Zarco JA, Marhx-Bracho A, Rueda-Franco F, Bornstein-Quevedo L (2007) Long term survival in children under 3 years of age with low-grade astrocytoma. Childs Nerv Syst 23:543–547PubMedCrossRef Rivera-Luna R, Zapata-Tarres M, Medina-Sanson A, Lopez-Aguilar E, Niembro-Zuniga A, Zarco JA, Marhx-Bracho A, Rueda-Franco F, Bornstein-Quevedo L (2007) Long term survival in children under 3 years of age with low-grade astrocytoma. Childs Nerv Syst 23:543–547PubMedCrossRef
6.
Zurück zum Zitat Stiller CA, Bunch KJ (1992) Brain and spinal tumours in children aged under two years: incidence and survival in Britain, 1971-85. Br J Cancer 66:S50–S53 Stiller CA, Bunch KJ (1992) Brain and spinal tumours in children aged under two years: incidence and survival in Britain, 1971-85. Br J Cancer 66:S50–S53
7.
Zurück zum Zitat Gnekow A, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, Warmuth-Metz M, Herna´ iz Driever P, Soerensen N, Kortmann RD, Pietsch T, Faldum A (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro-Oncology 14:1265–1284PubMedCentralPubMedCrossRef Gnekow A, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, Warmuth-Metz M, Herna´ iz Driever P, Soerensen N, Kortmann RD, Pietsch T, Faldum A (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro-Oncology 14:1265–1284PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vexinz G, Wisoff JH, Pollack IF (2012) Randomized study of two chemotherapy regimens for treatment of low grade glioma in young children: a Children’s Oncology Group study. J Clin Oncol 3:2641–2647CrossRef Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vexinz G, Wisoff JH, Pollack IF (2012) Randomized study of two chemotherapy regimens for treatment of low grade glioma in young children: a Children’s Oncology Group study. J Clin Oncol 3:2641–2647CrossRef
Metadaten
Titel
Low grade astrocytoma in children under the age of three years: a report from the Canadian pediatric brain tumour consortium
verfasst von
Donna L. Johnston
Daniel Keene
Ute Bartels
Anne-Sophie Carret
Bruce Crooks
David D. Eisenstat
Chris Fryer
Lucie Lafay-Cousin
Valerie Larouche
Albert Moghrabi
Beverly Wilson
Shayna Zelcer
Mariana Silva
Eric Bouffet
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-015-1806-1

Weitere Artikel der Ausgabe 1/2015

Journal of Neuro-Oncology 1/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.